0
Orphan Designations
2
FDA Approvals
Latest: RYZUMVI (2023)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
Oyster Point Pharma, Inc. is a company with 0 orphan drug designations across 0 rare diseases, including 2 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.